Πηγή: Fierce Biotech | John
Carroll
The stats on Phase III success rates aren't good. About half end in
failure--and that's after developers have had a chance to do some careful
testing in humans. It's no wonder, then, that late-stage failures continue to
inflict some punishing damage on the world's largest R&D
organizations--which in most cases are still laboring to overcome the arrival
of the patent cliff.
I've singled out what I consider the most significant Phase III setbacks of
the year (so far). They were selected not just because they damaged or
destroyed estimates on peak sales, but because they also reflected on the companies
involved, influenced their research strategies or raised questions about a
disease initiative that had grabbed the attention of everyone in the field.
It doesn't always seem possible, but failure doesn't have to be solely
negative. The best organizations learn from their high-profile failures and the
setbacks of others. What's amazing is how often failure is still immediately
shoved out of public view, and how easy it is to convince analysts it was
either really a success or completely unimportant. The wake-up call on R&D
came long ago, but some groups are still fast asleep.